22 June 2022 - Krystal Biotech announced today the submission of a biologics license application to the U.S. FDA seeking approval of B-VEC (beremagene geperpavec) for the treatment of patients with dystrophic epidermolysis bullosa. 

B-VEC is an investigational non-invasive, topical gene therapy designed to treat DEB at the molecular level by providing the patient’s skin cells with two copies of the COL7A1 gene to make functional COL7 protein, thereby addressing the fundamental disease-causing mechanism.